State of the science: Molecular classifications of breast cancer for clinical diagnostics

Clinical Biochemistry

Volumn 37, Issue 7, 2004, Pages 572-578

  Robison, John E ^a   Perreard, Laurent ^b   Bernard, Philip S ^a,c  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b ARUP LABORATORIES   (United States)

^c UNIVERSITY OF UTAH   (United States)

Author keywords

Breast cancer; Genomics; Microarray

Indexed keywords

ANTHRACYCLINE; ANTIESTROGEN; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; FLUOROURACIL; FORMALDEHYDE; METHOTREXATE; PACLITAXEL; PARAFFIN; RNA; TAMOXIFEN; TRASTUZUMAB;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER STAGING; CANCER SURVIVAL; CARDIOTOXICITY; CORRELATION ANALYSIS; DNA MICROARRAY; DRUG MEGADOSE; GENE EXPRESSION; GENOMICS; HUMAN; METASTASIS; MORBIDITY; MORTALITY; NEUROTOXICITY; PATIENT CARE; PRIORITY JOURNAL; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; REVIEW; SERIAL ANALYSIS OF GENE EXPRESSION; SIDE EFFECT; STANDARDIZATION; TAXONOMY; TOXICITY; TUMOR CLASSIFICATION;

BREAST NEOPLASMS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOMICS; HUMANS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PREDICTIVE VALUE OF TESTS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 3042681114     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2004.05.002     Document Type: Review

References (71)

1. Landis SH, et al. Cancer Statistics, 1999. CA Cancer J Clin 1999;49(1):8-31 [1].
2. Lunardi G., et al. Influence of trastuzumab on epirubicin pharmacokinetics in metastatic breast cancer patients. Ann. Oncol. 14(8):2003;1222-1226
3. Wasserheit C., et al. Phase II trial of paclitaxel and cisplatin in women with advanced breast cancer: an active regimen with limiting neurotoxicity. J. Clin. Oncol. 14(7):1996;1993-1999
4. Linassier C., et al. Early secondary acute myelogenous leukemia in breast cancer patients after treatment with mitoxantrone, cyclophosphamide, fluorouracil and radiation therapy. Ann. Oncol. 11(10):2000;1289-1294
5. Chaplain G., et al. Increased risk of acute leukemia after adjuvant chemotherapy for breast cancer: a population-based study. J. Clin. Oncol. 18(15):2000;2836-2842
6. Bernard-Marty C., et al. Second malignancies following adjuvant chemotherapy: 6-year results from a Belgian randomized study comparing cyclophosphamide, methotrexate and 5-fluorouracil (CMF) with an anthracycline-based regimen in adjuvant treatment of node-positive breast cancer patients. Ann. Oncol. 14(5):2003;693-698
7. Smart C.R., et al. Twenty-year follow-up of the breast cancers diagnosed during the Breast Cancer Detection Demonstration Project. CA Cancer J. Clin. 47(3):1997;134-149
8. Rosen P.P., et al. Pathological prognostic factors in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma: a study of 644 patients with median follow-up of 18 years. J. Clin. Oncol. 7(9):1989;1239-1251
9. AJCC cancer staging handbook. Greene F., Page D., Fleming I., Fritz A., Balch C. Part VII - Breast. 6th edition:2002;257-281 Springer-Verlag, Chicago (IL)
10. Fitzgibbons P.L., et al. Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. Arch. Pathol. Lab. Med. 124(7):2000;966-978
11. Elston C.W., Ellis I.O. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 19(5):1991;403-410
12. Goldhirsch A., et al. Meeting highlights: international consensus panel on the treatment of primary breast cancer. Seventh international conference on adjuvant therapy of primary breast cancer. J. Clin. Oncol. vol. 19 (18):2001;3817-3827
13. Eifel P., et al. National institutes of health consensus development conference statement: adjuvant therapy for breast cancer, November 1-3, 2000. J. Natl. Cancer Inst. vol. 93 (13):2001;979-989
14. Aapro M.S. Adjuvant therapy of primary breast cancer: a review of key findings from the 7th international conference, St. Gallen, February 2001. Oncologist. vol. 6 (4):2001;376-385
15. Levine M.N., Bramwell V.H., Pritchard K.I., et al. Randomized trila of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer: National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 16:1998;2651-2658
16. Slamon D.J., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344(11):2001;783-792
17. Fisher B., et al. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J. Natl. Cancer. Inst. 93(9):2001;684-690
18. Fisher B., et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N. Engl. J. Med. 320(8):1989;479-484
19. Buzdar A., et al. Phase II, randomized, double-blind study of two dose levels of arzoxifene in patients with locally advanced or metastatic breast cancer. J. Clin. Oncol. 21(6):2003;1007-1014
20. Clarke R., et al. Cellular and molecular pharmacology of antiestrogen action and resistance. Pharmacol. Rev. 53(1):2001;25-71
21. Albanell J., Baselga J. Unraveling resistance to trastuzumab (Herceptin): insulin-like growth factor-I receptor, a new suspect. J. Natl. Cancer Inst. 93(24):2001;1830-1832
22. Bilous M., et al. Current perspectives on HER2 testing: a review of national testing guidelines. Mod. Pathol. 16(2):2003;173-182
23. Vogel C.L., et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J. Clin. Oncol. 20(3):2002;719-726
24. Cardoso F., et al. Resistance to trastuzumab: a necessary evil or a temporary challenge? Clin. Breast Cancer. 3(4):2002;247-257. (discussion 258-9.)
25. Hedenfalk I., et al. Gene-expression profiles in hereditary breast cancer. N. Engl. J. Med. 344(8):2001;539-548
26. Gruvberger S., et al. Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns. Cancer Res. 61(16):2001;5979-5984
27. Perou C.M., Brown P.O., Botstein D. Tumor classification using gene expression patterns from DNA microarrays. New technologies for life sciences: a trends guide. 2000;67-76 Elsevier Ltd.
28. Sørlie T., et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl. Acad. Sci. U. S. A. 98(19):2001;10869-10874
29. West M., et al. Predicting the clinical status of human breast cancer by using gene expression profiles. Proc. Natl. Acad. Sci. U. S. A. 98(20):2001;11462-11467
30. van 't Veer L.J., et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 415(6871):2002;530-536
31. Sotiriou C., et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc. Natl. Acad. Sci. U. S. A. 100(18):2003;10393-10398
32. Nutt C.L., et al. Gene expression-based classification of malignant gliomas correlates better with survival than histological classification. Cancer Res. 63(7):2003;1602-1607
33. Godard S., et al. Classification of human astrocytic gliomas on the basis of gene expression: a correlated group of genes with angiogenic activity emerges as a strong predictor of subtypes. Cancer Res. 63(20):2003;6613-6625
34. van den Boom J., et al. Characterization of gene expression profiles associated with glioma progression using oligonucleotide-based microarray analysis and real-time reverse transcription-polymerase chain reaction. Am. J. Pathol. 163(3):2003;1033-1043
35. Shai R., et al. Gene expression profiling identifies molecular subtypes of gliomas. Oncogene. 22(31):2003;4918-4923
36. Beer D.G., et al. Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat. Med. 8:2002;816-824
37. Garber M.E., et al. Diversity of gene expression in adenocarcinoma of the lung. Proc. Natl. Acad. Sci. U. S. A. 98(24):2001;13784-13789
38. Bhattacharjee A., et al. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc. Natl. Acad. Sci. U. S. A. 98(24):2001;13790-13795
39. Jazaeri A.A., et al. Gene expression profiles of BRCA1-linked, BRCA2-linked, and sporadic ovarian cancers. J. Natl. Cancer Inst. 94(13):2002;990-1000
40. Welsh J.B., et al. Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer. Proc. Natl. Acad. Sci. U. S. A. 98(3):2001;1176-1181
41. Singh D., et al. Gene expression correlates of clinical prostate cancer behavior. Cancer Cell. 1(2):2002;203-209
42. LaTulippe E., et al. Comprehensive gene expression analysis of prostate cancer reveals distinct transcriptional programs associated with metastatic disease. Cancer Res. 62(15):2002;4499-4506
43. Welsh J.B., et al. Analysis of gene expression identifies candidate markers and pharmacological targets in prostate cancer. Cancer Res. 61(16):2001;5974-5978
44. Dhanasekaran S.M., et al. Delineation of prognostic biomarkers in prostate cancer. Nature. 412(6849):2001;822-826
45. Hippo Y., et al. Global gene expression analysis of gastric cancer by oligonucleotide microarrays. Cancer Res. 62(1):2002;233-240
46. Hofmann W.K., et al. Relation between resistance of Philadelphia- chromosome-positive acute lymphoblastic leukaemia to the tyrosine kinase inhibitor STI571 and gene-expression profiles: a gene-expression study. Lancet. 359(9305):2002;481-486
47. Ferrando A.A., et al. Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. Cancer Cell. 1(1):2002;75-87
48. Yeoh E.J. Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell. 1(2):2002;133-143
49. Shipp M.A., et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat. Med. 8(1):2002;68-74
50. Rosenwald A., et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N. Engl. J. Med. 346(25):2002;1937-1947
51. Alizadeh A.A., et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling [see comments]. Nature. 403(6769):2000;503-511
52. Eisen M.B. Cluster analysis and display of genome-wide expression patterns. Proc. Natl. Acad. Sci. U. S. A. 95(25):1998;14863-14868
53. Perou C.M., et al. Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. Proc. Natl. Acad. Sci. U. S. A. 96(16):1999;9212-9217
54. Perou C.M., et al. Molecular portraits of human breast tumours. Nature. 406(6797):2000;747-752
55. Chung C.H., Bernard P.S., Perou C.M. Molecular portraits and the family tree of cancer. Nat. Genet. 32:2002;533-540. (Suppl)
56. Taylor-Papadimitriou J., et al. Keratin expression in human mammary epithelial cells cultured from normal and malignant tissue: relation to in vivo phenotypes and influence of medium. J. Cell Sci. 94(Pt 3):1989;403-413
57. Sorlie T., et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc. Natl. Acad. Sci. U. S. A. 100(14):2003;8418-8423
58. Jiang X., et al. Grb2 regulates internalization of EGF receptors through clathrin-coated pits. Mol. Biol. Cell. 14(3):2003;858-870
59. Pollack J.R., et al. Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors. Proc. Natl. Acad. Sci. U. S. A. 99(20):2002;12963-12968
60. Desai K.V., et al. Initiating oncogenic event determines gene-expression patterns of human breast cancer models. Proc. Natl. Acad. Sci. U. S. A. 99(10):2002;6967-6972
61. Tusher V., Tibshirani R., Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc. Natl. Acad. Sci. U. S. A. 98(9):2001;5116-5121
62. van de Vijver M.J., et al. A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med. 347(25):2002;1999-2009
63. Bernard P.S., Wittwer C.T. Real-time PCR technology for cancer diagnostics. Clin. Chem. 48(8):2002;1178-1185
64. Wittwer C.T., et al. Continuous fluorescence monitoring of rapid cycle DNA amplification. Biotechniques. 22(1):1997;130-1-134-8
65. Livak K.J. Oligonucleotides with fluorescent dyes at opposite ends provide a quenched probe system useful for detecting PCR product and nucleic acid hybridization. PCR Methods Appl. 4(6):1995;357-362
66. Tyagi S., Kramer F.R. Molecular beacons: probes that fluoresce upon hybridization. Nat. Biotechnol. 14(3):1996;303-308
67. Taveau M., et al. Quantification of splice variants using molecular beacon or scorpion primers. Anal. Biochem. 305(2):2002;227-235
68. Nazarenko I., et al. Multiplex quantitative PCR using self-quenched primers labeled with a single fluorophore. Nucleic Acids Res. 30(9):2002;e37
69. Morrison TB, Weis JJ, Wittwer CT. Quantification of low-copy transcripts by continuous SYBR Green I monitoring during amplification. Biotechniques 1998;24(6):954-8, 960, 962.
70. Wittwer C.T., Kusukawa N. Real-time PCR. Persing D., Tenover F., Relman D., White T., Tang Y., Versalovic J., Unger B. Diagnostic molecular microbiology: principles and applications. 2003;71-84 ASM Press
71. Frank S.G., Bernard P.S. Profiling breast cancer using real-time quantitative PCR. Meuer S., Wittwer C., Nakagawara K. Rapid cycle real-time PCR methods and applications. 2003;95-106 Springer, Heidelberg, Germany